Mallinckrodt plc Reports Q2 2025 Financial Results and Future Outlook
Mallinckrodt plc Reports Q2 2025 Financial Results and Future Outlook
Mallinckrodt plc, a prominent player in the pharmaceutical industry, has recently disclosed its financial performance for the second quarter of 2025, which ended on June 27, 2025. Despite posting a year-over-year decline in net sales, the company's leaders expressed optimism about the future following its recent merger with Endo, Inc., which officially took place on July 31, 2025.
Financial Highlights for Q2 2025
In the second quarter, Mallinckrodt reported net sales of $485.1 million, which indicates a 5.7% decrease from $514.3 million reported in the same quarter in 2024. However, removing the impact of the divestiture of its Therakos segment, net sales actually showcase an 8.5% increase.
Key performance indicators for the quarter include:
- - A net income of $2.4 million, an improvement from a loss of $43.3 million in Q2 2024.
- - An adjusted EBITDA of $137.2 million, down from $174 million the previous year. This reflects the company's mixed performance amidst transitional challenges.
- - The sales of Acthar® Gel saw significant growth, marking its highest quarterly growth in over ten years, with revenues reaching $175.1 million — up 48.8% year-over-year.
The Specialty Brands segment, which includes Acthar Gel, recorded net sales of $264.3 million, while the Specialty Generics segment contributed $220.8 million, revealing an overall solid performance despite certain competitive pressures.
Legacy Endo’s Contributions
The financial report also included results from legacy Endo for the quarter ending June 30, 2025, highlighting overall revenues of $447.8 million, showing minimal change compared to the previous year. However, excluding its divested international business segment, revenues grew by 2%. A notable driver for Endo was its XIAFLEX® product, which grew by 9.4% contributing $138.6 million to the revenues.
Guidance for the Future
Looking ahead, Mallinckrodt has provided full-year financial guidance, projecting total 2025 net sales between $3.57 billion to $3.62 billion, alongside an expected adjusted EBITDA of $1.10 billion to $1.13 billion. The firm anticipates net sales growth for its Acthar Gel product, updating the projection from a high-single-digit increase to between 20% and 30% for the remainder of 2025.
Siggi Olafsson, President and CEO of Mallinckrodt, emphasized the momentum built over the quarter, commending the strength shown by both legacy companies. He remarked, “We are excited about the opportunities this merger brings, and we are committed to accelerating growth and delivering value to our shareholders and customers.”
Strategic Moves Amidst Challenges
As part of ongoing strategic initiatives, the company is preparing for the planned spin-off of its Par Health division — focusing on generics and sterile injectables. This spin-off is on track to be realized by the end of 2025, contingent on board approval. Until the separation, Par Health will function as a fully owned entity within the newly merged company.
Mallinckrodt’s performance in Q2 2025 serves as a reflection of its resilience despite facing challenges, including significant market adjustments and operational changes following its merger. With high growth expectations for key product areas and a strong leadership team, the company aims to solidify its position in the pharmaceutical market.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.